Nepal

Reimbursed Care Access

Nepal maintains a restrictive national drug-control regime under the Narcotic Drugs (Control) Act, 2033 (1976), while conventional ketamine is an accepted, listed essential anaesthetic used in clinical care. Most classical psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X, and ayahuasca) have no authorized medical-market framework and are treated as controlled/narcotic substances under Nepal’s drug‑control law with no routine clinical or reimbursement pathways. Esketamine (Spravato) is not documented as an approved or routinely available reimbursed medication in Nepal’s public formulary and, unlike generic ketamine, has no established reimbursement or marketing footprint in the Nepalese health system.